ARIA
Library/hormonal/Ipamorelin

Ipamorelin

Not FDA Approved⛔ WADA Banned

NNA / GHRP

hormonal◆EmergingGhrelin receptor agonist (GHS-R1a)

Selective ghrelin mimetic. Stimulates GH release without affecting cortisol or appetite as much as other GHRPs. Often paired with CJC-1295. WADA banned.

Confidence
48%
Half-Life ~2 hours
Cost ~$200/mo
Quick Reference
Routesubcutaneous
MechanismSelective agonist at GHS-R1a (ghrelin receptor) on pituitary and hypothalamus → ...
SequenceAib-His-D-2-Nal-D-Phe-Lys-NH2
Mol. Weight711.9 Da
Reviewed2026-07-08

Mechanism of Action

Selective agonist at GHS-R1a (ghrelin receptor) on pituitary and hypothalamus → GH release. More selective than GHRP-6: minimal cortisol/prolactin elevation, minimal appetite stimulation.

Dosing Protocol

100-200μg SC, 1-3x daily (fasting). Paired with CJC-1295 1:1 ratio. Cycle 3-6 months.

Key Studies

2026

Injectable peptide therapy primer

PMID 41476424narrative_review
2015

GHRP metabolites doping analysis

PMID 25869809analytical

Adverse Effects

FlushingIncreased appetite (mild)Water retentionInjection site reactions

Contraindications

  • Active malignancy
  • Pregnancy
  • Competitive athletes

Storage

Lyophilized: refrigerate or freeze. Reconstituted: refrigerate 2-8°C, use within 30 days.

Clinical Applications

  • ["hormonal_optimization"
  • "recovery"
  • "anti_aging"
  • "body_composition"]